IL322955A - Tasty compositions containing sodium phenylbutyrate and their uses - Google Patents
Tasty compositions containing sodium phenylbutyrate and their usesInfo
- Publication number
- IL322955A IL322955A IL322955A IL32295525A IL322955A IL 322955 A IL322955 A IL 322955A IL 322955 A IL322955 A IL 322955A IL 32295525 A IL32295525 A IL 32295525A IL 322955 A IL322955 A IL 322955A
- Authority
- IL
- Israel
- Prior art keywords
- total weight
- taste
- pharmaceutical composition
- less
- sodium phenylbutyrate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/501—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662308614P | 2016-03-15 | 2016-03-15 | |
| PCT/US2016/057415 WO2017160345A1 (en) | 2016-03-15 | 2016-10-17 | Palatable compositions including sodium phenylbutyrate and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL322955A true IL322955A (en) | 2025-10-01 |
Family
ID=59847918
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL322955A IL322955A (en) | 2016-03-15 | 2016-10-17 | Tasty compositions containing sodium phenylbutyrate and their uses |
| IL296490A IL296490B2 (en) | 2016-03-15 | 2016-10-17 | Tasty compositions containing sodium phenylbutyrate and their uses |
| IL261777A IL261777B2 (en) | 2016-03-15 | 2018-09-13 | Palatable compositions including sodium phenylbutyrate and uses thereof |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL296490A IL296490B2 (en) | 2016-03-15 | 2016-10-17 | Tasty compositions containing sodium phenylbutyrate and their uses |
| IL261777A IL261777B2 (en) | 2016-03-15 | 2018-09-13 | Palatable compositions including sodium phenylbutyrate and uses thereof |
Country Status (22)
| Country | Link |
|---|---|
| US (6) | US20170266115A1 (enExample) |
| EP (2) | EP3429559B1 (enExample) |
| JP (4) | JP7136763B2 (enExample) |
| KR (3) | KR102690703B1 (enExample) |
| AU (1) | AU2016398029B2 (enExample) |
| BR (1) | BR112018068665B1 (enExample) |
| CY (1) | CY1125450T1 (enExample) |
| DK (1) | DK3429559T3 (enExample) |
| ES (1) | ES2922749T3 (enExample) |
| HR (1) | HRP20220856T1 (enExample) |
| HU (1) | HUE059630T2 (enExample) |
| IL (3) | IL322955A (enExample) |
| LT (1) | LT3429559T (enExample) |
| MX (2) | MX391305B (enExample) |
| PL (1) | PL3429559T3 (enExample) |
| PT (1) | PT3429559T (enExample) |
| RS (1) | RS63383B1 (enExample) |
| SA (1) | SA518400020B1 (enExample) |
| SG (1) | SG11201807979SA (enExample) |
| SI (1) | SI3429559T1 (enExample) |
| SM (1) | SMT202200386T1 (enExample) |
| WO (1) | WO2017160345A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX391305B (es) | 2016-03-15 | 2025-03-21 | Acer Therapeutics Inc | Composiciones degustables que incluyen fenilbutirato de sodio y usos de las mismas. |
| US11583542B2 (en) * | 2019-12-16 | 2023-02-21 | Amylyx Pharmaceuticals, Inc. | Compositions of bile acids and phenylbutyrate compounds |
| WO2022011061A1 (en) * | 2020-07-07 | 2022-01-13 | Acer Therapeutics Inc. | Methods of administering taste masked phenylbutyrate and compositions therefor |
| EP4247354A4 (en) * | 2020-11-18 | 2025-02-19 | Fb-Hrs, Llc | COMPOSITIONS CONTAINING DOFETILIDE AND MEXILETINE AND THEIR USES |
| CN113332267A (zh) * | 2021-03-31 | 2021-09-03 | 中山大学孙逸仙纪念医院 | 苯丁酸钠在制备预防或治疗帕金森病的药物中的应用 |
| IT202100019613A1 (it) | 2021-07-23 | 2023-01-23 | Kolfarma S R L | Formulazione farmaceutica o di integratore alimentare contenente alfa-lattoalbumina e acido butirrico o un suo sale |
| CN216570857U (zh) * | 2021-08-11 | 2022-05-24 | Acer治疗公司 | 改善药物物质适口性的剂型和多个剂型 |
| IL315049A (en) * | 2024-08-15 | 2026-03-01 | Prilenia Neurotherapeutics Ltd | Taste-masked pridopidine formulations, method of use thereof and process for preparation thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5910304A (en) | 1982-12-13 | 1999-06-08 | Texas A&M University System | Low-dose oral administration of interferons |
| CA1320905C (en) | 1986-11-06 | 1993-08-03 | Joseph M. Cummins | Treatment of immuno-resistant disease |
| US6036949A (en) | 1998-03-05 | 2000-03-14 | Amarillo Biosciences, Inc. | Treatment of fibromyalgia with low doses of interferon |
| AR034813A1 (es) | 2001-07-20 | 2004-03-17 | Novartis Ag | Composiciones farmaceuticas y uso de las mismas |
| EP1291015A1 (en) | 2001-09-10 | 2003-03-12 | Lunamed AG | Dosage forms having prolonged active ingredient release |
| US20040152784A1 (en) * | 2002-07-23 | 2004-08-05 | Special Products Limited | Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia |
| FR2850275B1 (fr) | 2003-01-24 | 2005-04-08 | Scherer Technologies Inc R P | Capsules molles a macher contenant une substance active a gout masque |
| JP2005060310A (ja) | 2003-08-13 | 2005-03-10 | Towa Yakuhin Kk | 不快な味をマスキングする経口投与用製剤 |
| US6984403B2 (en) | 2003-12-04 | 2006-01-10 | Pfizer Inc. | Azithromycin dosage forms with reduced side effects |
| ATE378042T1 (de) * | 2004-04-12 | 2007-11-15 | Pfizer Prod Inc | Arzneiimittel mit verdecktem geschmack in aufbrechenden multipartikeln |
| US8821928B2 (en) * | 2007-06-04 | 2014-09-02 | Egalet Ltd. | Controlled release pharmaceutical compositions for prolonged effect |
| ES2332687B1 (es) | 2008-03-13 | 2011-01-10 | Proyecto De Biomedicina Cima, S.L. | Nuevos usos de 4pba y sus sales farmaceuticamente aceptables. |
| US20100136110A1 (en) * | 2008-09-30 | 2010-06-03 | Astellas Pharma Inc. | Granular pharmaceutical composition for oral administration |
| EP2954780A1 (en) | 2009-07-24 | 2015-12-16 | Baylor College Of Medicine | Methods of modulation of branched chain acids and uses thereof |
| FR2959129B1 (fr) * | 2010-04-21 | 2013-02-01 | Lucane Pharma | Particules comprenant du 4-phenylbutyrate de sodium, procede de preparation et utilisations |
| EP2389932A1 (en) * | 2010-05-28 | 2011-11-30 | Lunamed AG | Compositions for use in genetic disorders comprising 4-phenyl-butyric acid and its salts |
| WO2012077038A1 (en) | 2010-12-06 | 2012-06-14 | Degama Berrier Ltd. | Composition and method for improving stability and extending shelf life of probiotic bacteria and food products thereof |
| US8897280B2 (en) * | 2011-03-29 | 2014-11-25 | Qualcomm Incorporated | System and method for clear channel assessment that supports simultaneous transmission by multiple wireless protocols |
| EP2709593A4 (en) * | 2011-05-16 | 2014-10-29 | Sun Pharma Advanced Res Co Ltd | PHARMACEUTICAL COMPOSITION OF MULTIPLE PARTICLES |
| JP2012240917A (ja) | 2011-05-16 | 2012-12-10 | Zensei Yakuhin Kogyo Kk | 製剤化用微粒子とそれを含む製剤 |
| CN103687496A (zh) | 2011-06-07 | 2014-03-26 | Spai集团有限公司 | 用于改善敏感性食品添加剂及其食品产品的稳定性并且延长其货架期的组合物和方法 |
| JP2014517057A (ja) * | 2011-06-22 | 2014-07-17 | ジーエムピー‐オーファン | 運動ニューロン疾患または代謝性疾患の治療のための直腸形態のフェニル酪酸塩 |
| KR20140057604A (ko) * | 2011-08-12 | 2014-05-13 | 베링거잉겔하임베트메디카게엠베하 | 고양잇과 동물의 심부전을 치료 및 예방하는 방법에 사용하기 위한 퍼니 전류 억제제 |
| EP2599477A1 (en) * | 2011-11-30 | 2013-06-05 | Lunamed AG | 4-Phenylbutyric acid sustained release formulation |
| US8993041B2 (en) | 2012-10-15 | 2015-03-31 | New Jersey Institute Of Technology | Taste masked active pharmaceutical powder compositions and processes for making them |
| CN105560203A (zh) | 2013-01-28 | 2016-05-11 | 万平 | 定位速释生物粘附剂及其制备方法和应用 |
| JP6147711B2 (ja) | 2014-05-26 | 2017-06-14 | 富士フイルム株式会社 | 医薬用組成物及びその製造方法、並びに口腔内崩壊錠及びその製造方法 |
| MX391305B (es) | 2016-03-15 | 2025-03-21 | Acer Therapeutics Inc | Composiciones degustables que incluyen fenilbutirato de sodio y usos de las mismas. |
-
2016
- 2016-10-17 MX MX2018011229A patent/MX391305B/es unknown
- 2016-10-17 PL PL16894786.9T patent/PL3429559T3/pl unknown
- 2016-10-17 US US15/295,881 patent/US20170266115A1/en not_active Abandoned
- 2016-10-17 PT PT168947869T patent/PT3429559T/pt unknown
- 2016-10-17 EP EP16894786.9A patent/EP3429559B1/en active Active
- 2016-10-17 EP EP22167705.7A patent/EP4104822A1/en active Pending
- 2016-10-17 ES ES16894786T patent/ES2922749T3/es active Active
- 2016-10-17 IL IL322955A patent/IL322955A/en unknown
- 2016-10-17 JP JP2019500212A patent/JP7136763B2/ja active Active
- 2016-10-17 IL IL296490A patent/IL296490B2/en unknown
- 2016-10-17 SG SG11201807979SA patent/SG11201807979SA/en unknown
- 2016-10-17 KR KR1020187029452A patent/KR102690703B1/ko active Active
- 2016-10-17 AU AU2016398029A patent/AU2016398029B2/en active Active
- 2016-10-17 LT LTEPPCT/US2016/057415T patent/LT3429559T/lt unknown
- 2016-10-17 KR KR1020257031993A patent/KR20250150154A/ko active Pending
- 2016-10-17 WO PCT/US2016/057415 patent/WO2017160345A1/en not_active Ceased
- 2016-10-17 HR HRP20220856TT patent/HRP20220856T1/hr unknown
- 2016-10-17 SM SM20220386T patent/SMT202200386T1/it unknown
- 2016-10-17 DK DK16894786.9T patent/DK3429559T3/da active
- 2016-10-17 SI SI201631567T patent/SI3429559T1/sl unknown
- 2016-10-17 RS RS20220651A patent/RS63383B1/sr unknown
- 2016-10-17 HU HUE16894786A patent/HUE059630T2/hu unknown
- 2016-10-17 KR KR1020247025507A patent/KR102865751B1/ko active Active
- 2016-10-17 BR BR112018068665-4A patent/BR112018068665B1/pt active IP Right Grant
-
2018
- 2018-09-13 IL IL261777A patent/IL261777B2/en unknown
- 2018-09-13 SA SA518400020A patent/SA518400020B1/ar unknown
- 2018-09-14 MX MX2022003969A patent/MX2022003969A/es unknown
-
2020
- 2020-01-17 US US16/746,186 patent/US11433041B2/en active Active
-
2021
- 2021-03-09 US US17/196,416 patent/US11154521B2/en active Active
- 2021-03-09 US US17/196,599 patent/US11202767B2/en active Active
-
2022
- 2022-05-09 JP JP2022076939A patent/JP2022106927A/ja not_active Withdrawn
- 2022-07-12 CY CY20221100475T patent/CY1125450T1/el unknown
- 2022-09-02 US US17/902,358 patent/US20230133629A1/en not_active Abandoned
-
2024
- 2024-03-29 JP JP2024055290A patent/JP2024081748A/ja active Pending
-
2025
- 2025-07-31 US US19/287,366 patent/US20260076927A1/en active Pending
- 2025-11-10 JP JP2025188821A patent/JP2026027401A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260076927A1 (en) | Palatable compositions including sodium phenylbutyrate and uses thereof | |
| ES2606463T3 (es) | Combinación de formas de dosificación de levodopa/carbidopa de liberación inmediata y liberación controlada | |
| US20100203119A1 (en) | Pharmaceutical treatment process using chitosan or derivative thereof | |
| US10881614B2 (en) | Nicotinamide compositions and the therapeutic use thereof | |
| BRPI0621633A2 (pt) | composição farmacêutica, método para tratar distúrbio de déficit de atenção por hiperatividade (adhd) e composição farmacêutica de liberação sustentada | |
| JP7652763B2 (ja) | イブジラスト経口製剤およびその使用方法 | |
| CA3017573C (en) | Palatable compositions including sodium phenylbutyrate and uses thereof | |
| WO2008068778A2 (en) | Extended release pharmaceutical composition of pramipexole | |
| JP2003512311A (ja) | Ｃｎｓ介在性障害を治療するための持続放出製剤 | |
| US20220241367A1 (en) | Treatment of Abdominal Pain Associated with Diarrhea-Predominant Irritable Bowel Syndrome | |
| JP2024524757A (ja) | 多粒子医薬組成物 |